The energy efficient synthesis of complex molecules from readily accessible starting materials remains a key challenge of the natural sciences, catalysis can address this important challenge. This project draws together the dispar...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
NATCAT
Emulating Nature through Asymmetric Catalysis
1M€
Cerrado
ASYNO2
ASYNO2: Providing unprecedented concepts for the access of e...
333K€
Cerrado
CTQ2011-23620
NUEVOS LIGANDOS Y CATALIZADORES DE SINTESIS ASIMETRICA: APLI...
295K€
Cerrado
CTQ2017-84767-P
METODOS SINTETICOS EFICIENTES BASADOS EN CATALISIS METALICA....
59K€
Cerrado
CTQ2016-78580-C2-2-R
DESARROLLO DE NUEVOS SISTEMAS MOLECULARES Y SUPRAMOLECULARES...
97K€
Cerrado
Información proyecto SRANC
Líder del proyecto
Henan Normal University
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
15K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The energy efficient synthesis of complex molecules from readily accessible starting materials remains a key challenge of the natural sciences, catalysis can address this important challenge. This project draws together the disparate disciplines of catalysis and sensing to deliver new understanding and new functionality towards the synthesis of the next generation of molecules for health. By exploiting the best technology in the sensing arena in combination with synthetic expertise will offer a new paradigm in the approach to tackling synthetic challenges that the team draw together here is ideally equipped to tackle and deliver significant scientific and societal benefits.
New catalysts which can sense their own efficacy will be at the heart of the proposed research. Through rapid screening facilitated by the unique sensing regime translated from chemical sensors into catalysis will permit new and exciting synthesis be realised. As such drug molecules that were previously inaccessible for commercial exploitation due to efficiency and selectivity concerns will be realised.